General Information of Drug (ID: DMGROQP)

Drug Name
FK-505 Drug Info
Synonyms FR-76505; 2-[3-(4-Bromo-2-fluorobenzyl)-7-fluoro-2,4-dioxo-1,2,3,4-tetrahydroquinazolin-1-yl]acetic acid
Indication
Disease Entry ICD 11 Status REF
Hyperuricaemia 5C55.Y Phase 2 [1]
Cross-matching ID
PubChem CID
3086955
CAS Number
CAS 112733-08-1
TTD Drug ID
DMGROQP

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Discontinued Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Ascrolimus DMZF68E Psoriasis vulgaris EA90 Phase 2 [3]
Timcodar dimesilate DMDJLX7 Solid tumour/cancer 2A00-2F9Z Phase 1/2 [4]
T-506 DM7XGJY Solid tumour/cancer 2A00-2F9Z Discontinued in Phase 2 [5]

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
FK506-binding protein (FKBP) TTFH2RS NOUNIPROTAC Modulator [2]

References

1 X-Ray Powder Diffraction Study on the Grinding Effect of the Polymorphs of a Novel and Orally Effective Uricosuric Agent: FR76505. Volume 20, Issue 18, 1994.
2 Prevention of Cardiac Hypertrophy by Calcineurin Inhibition. Circulation Research. 1999; 84: 623-632.
3 Mode of action of tacrolimus (FK506): molecular and cellular mechanisms. Ther Drug Monit. 1995 Dec;17(6):584-91.
4 Analysis of FK506, timcodar (VX-853) and FKBP51 and FKBP52 chaperones in control of glucocorticoid receptor activity and phosphorylation. Pharmacol Res Perspect. 2014 December; 2(6): e00076.
5 EP patent application no. 0831812, Methods and compositions for stimulating neurite growth.